Date: 2012-09-20
Type of information: R&D agreement
Compound: novel compounds against tuberculosis
Company: Sanofi (France) TB Alliance
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease: tuberculosis
Details: Sanofi and the Global Alliance for TB Drug Development (TB Alliance) have announced a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis. Under the agreement, Sanofi and TB Alliance will collaborate to further optimize and develop several novel compounds in Sanofi’s library that have demonstrated activity against Mycobacterium tuberculosis, the bacterium that causes TB. This includes in-depth research of lead compounds based upon identified chemical derivatives of natural products, which have promising potential to treat all forms of tuberculosis, and the chemical optimization of other series of compounds that have been identified as hits through high-throughput screening.
Financial terms:
Latest news:
